All News

Inflammation,reflex,neural

Inflammatory Arthritis Spread by ATP and Neural Crosstalk

Jack Cush, MD

A novel study from the Journal of Experimental Medicine suggests that a reflex neural signaling at sites of inflammation may lead to spread to other inflammatory sites via and ATP-mediated neural crosstalk.

Read Article
morbidity,covid,heart,lung,brain

Multimorbidity Burden in Rheumatoid Arthritis

Jack Cush, MD

Crowson and colleagues at the Mayo Clinic have shown that rheumatoid arthritis (RA) patients have a higher prevalence of multimorbidity with as many as 44 different morbidities of interest in RA.

Read Article
Methotrexate

Can You Reduce Frequency of Methotrexate Monitoring?

Jack Cush, MD

Observational research presented at the British Society for Rheumatology meeting suggest that, based on the COVID-19 pandemic experience, reduced frequency of routine lab monitoring in patients receiving weekly methotrexate therapy for rheumatoid arthritis (RA) was not associated with an increase in adverse outcomes.

Read Article
RA.Ow02.jpg

ASCORE: Seropositivity Favors Abatacept Drug Survival

Jack Cush, MD

The ASCORE (Abatacept SubCutaneOus in Routine clinical practicE) study evaluated efficacy, safety, and drug retention (durability) of abatacept (ABA) moderate-to-severe rheumatoid arthritis (RA) and found consistently better ABA durability in those who were seropositive. 

Read Article
Patient,instruction

Making You the Expert of You! (Smart Rules for Patients)

Jack Cush, MD

You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.

Read Article
RheumNow Podcast square

What is JAKne? (5.6.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports, FDA actions, new side effects and changing prevalence of Gout.

Read Article
Ontario population study shows that musculoskeletal disorders account for 12.3% of all adult emergency dept. visits and 28.5% outpatient physician visits https://t.co/Sq9n7RkIYK https://t.co/lKtQqR5Ja3

Links:

Dr. John Cush RheumNow ( View Tweet)
RCT (WBC) whole body cryotherapy (-130C x 3 min; 6 WBC in 14 d) in 56 RA pts. Pain at 2 wks was signif better in WBC than controls (-2 vs -0.88 ; p=0.003) & remained lower x 12 weeks (w less pain meds); Dz activity & Function improved but not signif @wk 12 https://t.co/K7a7CQ7rGj https://t.co/a8QgiDeJS6

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Pregnancy Paradox: How Stopping Drugs Leads to Greater Harm Uma Mahadevan, MD talks about the pregnancy paradox and how stopping medications in pregnancy to protect the fetus can actually lead to greater harm. https://t.co/HYO5BdjwzZ https://t.co/IGeZ3O8Dno

Links:

Dr. John Cush RheumNow ( View Tweet)
Large Granular Lymphocyte Leukemia rarely assoc w/ #RA. LGL accounts for 2-5% of lymphoprolif. disorders; often assoc w/ Autoimmune Dz (mostly RA). RA w/ LGL presents with leukopenia, anemia, splenomegaly, onset after mean 6 yrs of RA https://t.co/AIz2edHDXp https://t.co/DoHKm3KS7d

Links:

Dr. John Cush RheumNow ( View Tweet)
Machine Learning helps predict RA relapse: data from KURAMA, 210 RA pts (150 achieved remission; 60 relapsed). Using clinical, lab and US findings, ML identified US findings in wrist and MTP predictors of relapse https://t.co/9rhctim4Mh https://t.co/iK3JudOMsC

Links:

Dr. John Cush RheumNow ( View Tweet)
ASCORE: Seropositivity Favors Abatacept Drug Survival The ASCORE study evaluated efficacy, safety, and drug retention (durability) of ABA in moderate-to-severe RA and found consistently better ABA durability in those who were seropositive. https://t.co/dLFC3dW4Tv https://t.co/LNCUIQjnGf

Links:

Dr. John Cush RheumNow ( View Tweet)
Early inflammatory arthritis pts (n=35,807; 86% White & 5,164 ethnic minority). Whites & minorities were equally seen by rheum <3 wks & started on Rx < 6wks, <inorities had less remission @3 mos (OR 0.79) or recv MTX 1st or steroids(0.68-0.63) https://t.co/rK7GLt5n1X https://t.co/uUwBBCnyGL

Links:

Dr. John Cush RheumNow ( View Tweet)
Making You the Expert of You! (Smart Rules for Patients) You’ve scheduled an appointment with your medical provider - how do you make the most of it? https://t.co/62mTqk4ksL https://t.co/gr7Hvt7EI3

Links:

Dr. John Cush RheumNow ( View Tweet)
Prophylaxis against pneumocystis pneumonia in RA patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry https://t.co/zeDQpP1NEH proph reduced PCP by 3/1000 per yr, 5 pts PCP despite proph, 80% on MTX & 11% cease proph due to AEs!

Links:

Peter Nash drpnash ( View Tweet)

Evobrutinib, selective oral BTK inhibitor, has been studied in >1083 pts in phase 3 RCTs of RA, SLE, MS; shows well tolerated, most common AE ≥5% UTI (9.5%), nasopharyngitis (7.3%), diarrhea (6.2%), transient ^LFTs, SIE rate 2.72/100 PYs https://t.co/NTKYOAHhln https://t.co/oUKCDicjyA

Links:

Dr. John Cush RheumNow ( View Tweet)
Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritis https://t.co/5dXe0AdNzE https://t.co/eS4KdaKBmC

Links:

Dr. John Cush RheumNow ( View Tweet)
An increasing incidence of RA is driven by increasing # of ACPA-negative RA (but not ACPA-positive RA), partly explained by an ageing population (thus making ACPA-negative RA more prevalent in coming years) https://t.co/9vC8aCphKc

Links:

Dr. John Cush RheumNow ( View Tweet)

Trends in RA Disability, Despite Biologics Disability claims in the U.S. related to RA were just as common in 2015 as in 1999, a gov't researcher found, against expectations that the advent of biologic therapy would have led to a steady decrease. https://t.co/vyyjTbkLN2 https://t.co/D5Eo42P4cw

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 17 homeless RA or PsA pts - less clinic access (80% vs 91%), more ED use (20 vs 5), less DMARDs (43% vs 100%), more steroids (29% vs 0%); 83% unable to work due to health. Greatest need - dental , PT, knee surgery, employment & housing https://t.co/VHnTR0MTkr https://t.co/JDZTELz2qB

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×